You are here

APHIS approves new Boehringer Ingelheim circovirus vaccine

Boehringer Ingelheim Vetmedica, Inc., (BIVI) announced this week that it has received approval from the U.S. Animal and Plant Health Inspection Service for a new vaccine called Ingelvac CircoFLEX to protect swine against diseases caused by porcine circovirus type-2 (PCV2).

According to Klaas Okkinga, BIVI marketing manager, Ingelvac CircoFLEX is a single-dose vaccine that provides efficacy and safety to pigs.

"It's effective in immunizing pigs as young as three weeks of age prior to exposure to PCV2, and provides protection without the systemic irritation and tissue reactions some vaccines can cause," Okkinga says.

In addition, Ingelvac CircoFLEX has a 21-day withdrawal period and positive pork quality assurance benefits that are important to producers, Okkinga adds. "It has been thoroughly field tested and we are confident this vaccine will help producers more effectively prevent porcine circovirus associated disease."

Ingelvac CircoFLEX will be available to producers in the first quarter of 2007.

Boehringer Ingelheim Vetmedica, Inc., (BIVI) announced this week that it has received approval from the U.S. Animal and Plant Health Inspection Service for a new vaccine called Ingelvac CircoFLEX to protect swine against diseases caused by porcine circovirus type-2 (PCV2).

Read more about